CN104856957B - 一种天门冬酰胺酶环糊精脂质体及其制备方法 - Google Patents
一种天门冬酰胺酶环糊精脂质体及其制备方法 Download PDFInfo
- Publication number
- CN104856957B CN104856957B CN201510292615.0A CN201510292615A CN104856957B CN 104856957 B CN104856957 B CN 104856957B CN 201510292615 A CN201510292615 A CN 201510292615A CN 104856957 B CN104856957 B CN 104856957B
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- asparaginase
- liposome
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 79
- 229960003272 ASPARAGINASE Drugs 0.000 title claims abstract description 67
- 102000015790 Asparaginase Human genes 0.000 title claims abstract description 67
- 108010024976 Asparaginase Proteins 0.000 title claims abstract description 67
- 239000002502 liposome Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 229940088598 Enzyme Drugs 0.000 claims description 18
- 229940107161 Cholesterol Drugs 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 15
- 239000007853 buffer solution Substances 0.000 claims description 12
- 229960001230 Asparagine Drugs 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 235000009582 asparagine Nutrition 0.000 claims description 9
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 8
- 102000005922 Amidases Human genes 0.000 claims description 8
- 108020003076 Amidases Proteins 0.000 claims description 8
- ODLHGICHYURWBS-LKONHMLTSA-N Trappsol Cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 8
- HFHDHCJBZVLPGP-RWMJIURBSA-N α-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002390 rotary evaporation Methods 0.000 claims description 6
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 5
- GDSRMADSINPKSL-HSEONFRVSA-N γ-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drugs Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 230000002708 enhancing Effects 0.000 description 5
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108060005858 parA Proteins 0.000 description 3
- 241000234427 Asparagus Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101710009148 SERPINA1 Proteins 0.000 description 2
- 230000001475 anti-trypsic Effects 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 230000036868 Blood Concentration Effects 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N Cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 Cinnarizine Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 230000035683 MEAN RESIDENCE TIME Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940112824 Paste Drugs 0.000 description 1
- 210000002706 Plastids Anatomy 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 125000000254 aspartoyl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000090 phagocyte Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- -1 phosphatidase 2 part Chemical compound 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510292615.0A CN104856957B (zh) | 2015-06-01 | 一种天门冬酰胺酶环糊精脂质体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510292615.0A CN104856957B (zh) | 2015-06-01 | 一种天门冬酰胺酶环糊精脂质体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104856957A CN104856957A (zh) | 2015-08-26 |
CN104856957B true CN104856957B (zh) | 2018-08-31 |
Family
ID=
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1748790A (zh) * | 2005-09-16 | 2006-03-22 | 北京双鹭药业股份有限公司 | 一种天门冬酰胺酶注射液、其制备方法及应用 |
CN101926962A (zh) * | 2010-08-20 | 2010-12-29 | 南京中医药大学 | 一种莪术油的羟丙基-β-环糊精包合物脂质体及其制备方法 |
CN104338124A (zh) * | 2014-09-19 | 2015-02-11 | 重庆医科大学 | 载天门冬酰胺酶的自组装聚乙二醇-透明质酸/环糊精纳米粒 |
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1748790A (zh) * | 2005-09-16 | 2006-03-22 | 北京双鹭药业股份有限公司 | 一种天门冬酰胺酶注射液、其制备方法及应用 |
CN101926962A (zh) * | 2010-08-20 | 2010-12-29 | 南京中医药大学 | 一种莪术油的羟丙基-β-环糊精包合物脂质体及其制备方法 |
CN104338124A (zh) * | 2014-09-19 | 2015-02-11 | 重庆医科大学 | 载天门冬酰胺酶的自组装聚乙二醇-透明质酸/环糊精纳米粒 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Elkhoury et al. | Engineering smart targeting nanovesicles and their combination with hydrogels for controlled drug delivery | |
JPH09511252A (ja) | 認識物質をリポソームに結合させる方法 | |
CN109364263A (zh) | 一种功能化的血小板仿生智能载体及其抗缺血性脑卒中应用 | |
CN102139112B (zh) | 药物载体原料及其制备方法和应用 | |
RU2682249C2 (ru) | рН-ЧУВСТВИТЕЛЬНЫЙ НОСИТЕЛЬ И СПОСОБ ЕГО ПОЛУЧЕНИЯ, И рН-ЧУВСТВИТЕЛЬНОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, И рН-ЧУВСТВИТЕЛЬНАЯ ЛЕКАРСТВЕННАЯ КОМПОЗИЦИЯ, ГДЕ КАЖДОЕ ИЗ НИХ СОДЕРЖИТ НОСИТЕЛЬ, И СПОСОБ КУЛЬТИВИРОВАНИЯ С ИХ ПРИМЕНЕНИЕМ | |
CN104434791A (zh) | 一种改性白芨多糖衍生物纳米载体的制备及应用 | |
CN114306581A (zh) | 一种融合细胞膜包裹尿酸酶/过氧化氢酶脂质纳米粒及其制备方法 | |
CN106267248A (zh) | 一种载叶酸修饰介孔二氧化硅纳米粒的脂质超声微泡及其制备方法 | |
Fumoto et al. | Understanding in vivo fate of nucleic acid and gene medicines for the rational design of drugs | |
CN103626846B (zh) | 与MDSCs特异性结合的配体多肽及药物输送系统 | |
CN109091468B (zh) | 一种抗体、多肽和核酸组合治疗靶向载体及制法和用途 | |
Li et al. | Recent developments in delivery of microRNAs utilizing nanosystems for metabolic syndrome therapy | |
Çelik et al. | Preparation of superoxide dismutase loaded chitosan microspheres: characterization and release studies | |
Della Pelle et al. | Nucleic acid delivery with red-blood-cell-based carriers | |
Suyamud et al. | Silk fibroin-coated liposomes as biomimetic nanocarrier for long-term release delivery system in cancer therapy | |
CN103040910B (zh) | 一种鹿瓜多肽脂质体注射剂 | |
CN108096189A (zh) | 一种脂质体纳米颗粒及其药物组合物和应用 | |
Jing et al. | Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanoporter‐Encased Hydrogel Eradicates Bladder Carcinoma | |
CN106668874A (zh) | 基于核酸适体和细胞穿模肽的载带药物或纳米颗粒进入特定靶标细胞的方法 | |
CN113648289A (zh) | 一种肺癌细胞膜包裹精氨酸脱亚胺酶脂质纳米粒及其制备方法 | |
CN105055315B (zh) | 一种交联线粒体靶向阿霉素脂质体及其制备方法 | |
CN103830739A (zh) | 配体多肽ph1形成的药物输送系统及其用途 | |
CN103721269B (zh) | 脂质体保护的纳米金基因载体及其制备方法 | |
CN103990136B (zh) | 经皮给药系统及其制备方法和应用 | |
CN104856957B (zh) | 一种天门冬酰胺酶环糊精脂质体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Jingqing Inventor after: Wan Shengli Inventor after: He Dan Inventor after: Yan Zijun Inventor after: Zhang Yanfang Inventor before: Zhang Jingqing Inventor before: Wan Shengli Inventor before: He Dan Inventor before: Yan Zijun Inventor before: Zhang Yanfang Inventor before: Tan Qunyou |